Raptor Soars After Retrophin Is Said to Consider Bid

Updated on
  • Drugmaker also has attracted interest from other companies
  • No agreement has been reached, firms could decide against deal

Raptor Pharmaceutical Corp. jumped in early trading Thursday after Retrophin Inc., the pharmaceutical company founded by controversial entrepreneur Martin Shkreli, was said to be considering an acquisition of the company.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.